Civil society meaningful engagement into integrated health response on TB, HIV and viral hepatitis

A newly released policy brief is meant to help better understand the UN Common Position on Ending HIV, TB and Viral Hepatitis through Intersectoral Collaboration, and to present the best practices of civil society for integrated response on TB, HIV and viral hepatitis.

Read More →

TB survivors call on G20 to invest in new TB vaccines

TB Vax ARM launches a campaign calling on G20 governments to fulfil their funding and political commitments to develop new TB vaccines.

Read More →

Global TB progress at risk: COVID-19 and funding shortages undermine years of steady gains

TB deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

Read More →

Advocates urge Cepheid to reinstate plans to commercialize GeneXpert Omni

Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni, reiterating demands for Cepheid to reduce the price of GeneXpert tests to $5, inclusive of service and maintenance, across diseases.

Read More →

TAGline: Delivering on the promise of long-acting formulations

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.

Read More →

TAG's 2021 Pipeline Report: TB chapters released

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Read More →

International support for compulsory license to address access barriers to life-saving TB medicines

Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.

Read More →

Advocates ring the alarm on TB medicines and diagnostics stock outs across India

Civil society networks in India call for the Ministry of Health and Family Welfare and the National TB Elimination Program to take urgent action.

Read More →

New data shows COVID-19 combined with funding shortfalls are devastating efforts to end TB by 2030

Less than half of required funding has been provided globally with dramatic consequences as hundreds of thousands more die from TB.

Read More →

Substantial public investments in GeneXpert underscore need for affordable pricing

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

Read More →

Page 2 of 112 · Total posts: 10

←First 1 2 3 Last→